ECM Biomedical Expands Its Global Human Tissue Collaboration Network

Strengthening the Global Regenerative Medicine Supply Chain Through a High-Quality Human Tissue Platform

Issued by: ECM Biomedical – Marketing & Public Relations Department

Taipei, Taiwan — ECM Biomedical today announced the expansion of its global human tissue collaboration network through the establishment of a long-term strategic partnership with a U.S. nonprofit tissue procurement organization. This collaboration aims to strengthen international cooperation in human tissue procurement, preservation, quality management, and clinical applications, reinforcing the global regenerative medicine supply chain while supporting the development of safe, high-quality, and sustainable human tissue products.

The partnership represents a significant milestone in ECM Biomedical's global growth strategy. Through international collaboration, the Company will continue to enhance its capabilities in human tissue preservation technologies, quality management systems, and manufacturing excellence, establishing a human tissue supply platform aligned with international standards to deliver reliable, high-quality tissue-based solutions to healthcare providers worldwide.

Building an International Human Tissue Supply Network

Human tissue serves as the foundation of regenerative medicine. From donor screening and tissue procurement to processing, preservation, manufacturing, and clinical application, every stage requires rigorous quality management and regulatory compliance.

ECM Biomedical noted that the United States has long-established expertise in tissue banking and human tissue management. Through this strategic collaboration, the Company will further strengthen tissue sourcing, quality assurance, and global supply chain integration while adopting internationally recognized best practices for human tissue management. These efforts are expected to further enhance product quality, consistency, and clinical reliability.

Building a Comprehensive Human Tissue Portfolio

ECM Biomedical continues to advance its regenerative medicine platform through the development of a comprehensive portfolio of human tissue products. The Company's core product platforms currently include Amniotic Membrane, Acellular Dermal Matrix (ADM), and Human Bone Allografts, with continued expansion into additional tissue categories including skin, cartilage, fascia, and ligaments.

This integrated Human Tissue Portfolio supports a broad range of clinical specialties, including orthopedics, rehabilitation medicine, sports medicine, neurosurgery, reconstructive surgery, dentistry, and aesthetic medicine, providing clinicians with comprehensive solutions for tissue repair and regenerative therapies.

Advancing Regenerative Medicine Through International Quality Standards

ECM Biomedical continues to operate in accordance with Taiwan Food and Drug Administration (TFDA) Human Tissue Bank regulations while implementing quality management systems aligned with international standards.

The Company has established comprehensive processes covering tissue procurement, preservation, manufacturing, quality assurance, and full product traceability to ensure product safety, manufacturing consistency, and clinical reliability.

ECM Biomedical believes that expanding global collaboration in human tissue technologies will not only strengthen product quality and supply stability but also accelerate technological innovation and the clinical adoption of regenerative medicine, laying a solid foundation for future international growth.

Expanding Global Partnerships for the Future of Regenerative Medicine

Looking ahead, ECM Biomedical will continue to deepen strategic partnerships with international organizations, integrate global human tissue resources, and expand research and development, clinical collaboration, and international market opportunities.

Leveraging its comprehensive human tissue portfolio, proprietary technologies, and internationally aligned quality management systems, ECM Biomedical remains committed to advancing regenerative medicine through innovation and global collaboration. The Company will continue to strengthen its position as a leading human tissue regenerative medicine company in Asia while expanding its presence in the global healthcare market.